Crotamiton

Crotamiton is a drug that is used both as a scabicidal (for treating scabies) and as a general antipruritic (anti-itching drug). It is a prescription, lotion-based medicine that is applied to the whole body to get rid of the scabies parasite that burrows under the skin and causes itching.

Crotamiton
Clinical data
AHFS/Drugs.comMonograph
Pregnancy
category
  • C
ATCvet code
  • QP53AX04 (WHO)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.233.700
Chemical and physical data
FormulaC13H17NO
Molar mass203.28 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Use

For treating scabies, crotamiton should be applied to the whole body rather than a localized area. It is applied two or three times, with a 24-hour delay between applications, and the patient is asked to take a shower no sooner than after 48 hours. For children under 3 years, it is applied once daily. It can also be used to treat itching stemming from other causes, e.g. insect bites, in which case it is applied to the itching areas only, and repeated if necessary after 4 to 8 hours. Use near the eyes, or breaks in the skin, should be avoided.

Pharmacology

Crotamiton is toxic to the scabies mite,[1] The mechanism of action of crotamiton as a general antipruritic was reported, in which crotamiton inhibits TRPV4 (transient receptor potential vanilloid 4) channel that is expressed in the skin, primary sensory neurons, and so on.[2]

Pharmacokinetics

After topical application, crotamiton is absorbed systemically. It has an elimination half-life of 30.9 hours and 4.8-8.8% is excreted in the urine.[3]

Side effects

The most common side effect of crotamiton is skin irritation.

Trade name

Crotamiton is marketed under the trade names Eurax, which is manufactured by Ranbaxy Laboratories in the USA, and GlaxoSmithKline in the UK, and Euracin, which is manufactured by Green Cross in South Korea. In Germany, it is marketed under the brand name Crotamitex. In India, it is sold as Eurax by Ranbaxy Laboratories.

References
  1. Medscape drug information - mechanism of action
  2. Kittaka, H.; Yamanoi, Y.; Tominaga, M. (2017). "Transient receptor potential vanilloid 4 (TRPV4) channel as a target of crotamiton and its bimodal effects". Pflügers Archiv: European Journal of Physiology. 469 (10): 1313–1323. doi:10.1007/s00424-017-1998-7. PMID 28612138.
  3. Medscape drug information - pharmacokinetics
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.